Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion type Assertion NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_head.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion evidence source_evidence_literature NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion SIO_000772 22200442 NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion wasDerivedFrom befree-20150227 NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion wasGeneratedBy ECO_0000203 NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.